CANEUS has announced that the CANEUS Organization has partnered with the French Space Agency - CNES to host the international 'MNT Reliability for Aerospace' Workshop in Toulouse, France, from March 6-7, 2008.
Ener1, Inc., an alternative energy company, announced that the United States Senate approved funding of $1 million to its EnerDel subsidiary for research to develop, produce and evaluate superior battery technology for mass transit hybrid electric buses.
US demand for biocompatible materials will increase 6.6 percent annually to $3.7 billion in 2010. Gains will match the overall upward pace of end-use product shipments as stricter FDA pre-market approval and production standards mandate the upgrading of materials used in medical and dental implants and drug delivery systems.
Cymbet Corporation today announced that Dr. Stephen W. Downey, director of technology at Cymbet, presented at the Semiconductor Research Council/National Science Foundation Forum on Nano-Morphic Systems: Processes, Devices and Architectures.
ASML Holding NV and Carl Zeiss SMT today announce that each has signed an agreement with Canon Inc. for the global cross-license of patents in their respective fields of semiconductor lithography and optical components, used to manufacture integrated circuits.
BIND Biosciences, Inc., a privately held biopharmaceutical company developing 'smart' therapeutic targeted nanoparticles capable of controlled drug delivery to diseased tissue, announced today the appointment of Jim Wright, Ph.D., as Chief Scientific Officer.
Following on the heels of the largest counterfeiting bust in Canadian history, IDGLOBAL's Nano-Molecular Marking technology was lauded as being 'one of the hottest technologies' in anti-counterfeiting.
Yissum Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.
According to a new technical market research report, the global market for nanoparticles in electronic, magnetic and optoelectronic applications will be worth $521.9 million in 2007. This is expected to increase to over $1.7 billion by 2012, a compound average annual growth rate of 16.5%.
Nasdaq-listed Flamel Technologies said it has entered into a collaboration with Merck KGaA unit Merck Serono to investigate the applicability of Flamel's Medusa technology for the extended release of a therapeutic protein of Merck Serono's portfolio.
The New York Times today carries an article describing how nanotechnology companies, nurtured on billions of dollars in government grants and venture investments through most of this decade, are getting ready to go public.